Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 18, 2006

Santarus Hands Over OTC Rights for Zegerid Products to Schering-Plough

  • Santarus granted Schering-Plough HealthCare Products exclusive rights to commercialize Zegerid® branded immediate-release omeprazole products for the OTC market in the U.S. and Canada. Schering reports that according to A.C. Nielsen, a market research firm, the OTC market for heartburn products was approximately $1.1 billion for the 12 months ending mid-August 2006.

    Schering-Plough will be responsible for the development, manufacturing, and commercialization of OTC Zegerid products with the lower dosage strength of 20 mg of omeprazole for heartburn-related indications.

    Under the terms of the agreement, which are subject to review, Santarus will receive a $15-million upfront license fee payable following the effective date of the agreement and may receive up to an additional $65 million in milestone payments upon the achievement of certain regulatory and sales milestones. Santarus will also receive a royalty, subject to adjustment in certain circumstances, on net sales of any Zegerid OTC products sold by Schering-Plough under the license agreement. A portion of these royalties will be paid to the University of Missouri pursuant to a license agreement between Santarus and the University of Missouri.

    Santarus will continue to manufacture, promote, and sell Zegerid products in both 40-mg and 20-mg dosage strengths of omeprazole for their approved prescription indications in the U.S. for proton pump inhibitor products.


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »